Search Results

There are 10270 results for: content related to: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

  1. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  2. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  3. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  4. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  5. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2316–2323, Peter Jenner and J. William Langston

    Version of Record online : 23 SEP 2011, DOI: 10.1002/mds.23926

  6. Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

    Annals of the New York Academy of Sciences

    Volume 1122, Issue 1, December 2007, Pages: 155–168, ORLY WEINREB, TAMAR AMIT, ORIT BAR-AM and MOUSSA B.H. YOUDIM

    Version of Record online : 10 DEC 2007, DOI: 10.1196/annals.1403.011

  7. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Version of Record online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  8. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

    The Journal of Clinical Pharmacology

    Volume 52, Issue 5, May 2012, Pages: 620–628, Dr Jack J. Chen and Dr Jayne R. Wilkinson

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011406279

  9. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

    Movement Disorders

    Volume 24, Issue 4, 15 March 2009, Pages: 564–573, Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek and Cheryl J. Fitzer-Attas

    Version of Record online : 11 DEC 2008, DOI: 10.1002/mds.22402

  10. You have free access to this content
    Neuroprotection by Rasagiline: A New Therapeutic Approach to Parkinson's Disease?

    CNS Drug Reviews

    Volume 11, Issue 2, March 2005, Pages: 183–194, Fabio Blandini

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2005.tb00269.x

  11. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 10, October 2004, Pages: 1295–1305, Dr. John J. Thébault, Dr. Michel Guillaume and Dr. Ruth Levy

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.24.14.1295.43156

  12. Abstracts of The Movement Disorder Society's Twelfth International Congress of Parkinson's Disease and Movement Disorders

    Movement Disorders

    Volume 23, Issue S1, 15 May 2008, Pages: S1–S422,

    Version of Record online : 28 MAY 2008, DOI: 10.1002/mds.22133

  13. You have free access to this content
    The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

    Journal of Neurochemistry

    Volume 112, Issue 5, March 2010, Pages: 1131–1137, Orit Bar-Am, Orly Weinreb, Tamar Amit and Moussa B. H. Youdim

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1471-4159.2009.06542.x

  14. Liquid chromatographic resolution of racemic rasagiline and its analogues on a chiral stationary phase based on (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid

    Journal of Separation Science

    Volume 36, Issue 23, December 2013, Pages: 3682–3687, Kyung Mi Tak, Eun Ju Park and Myung Ho Hyun

    Version of Record online : 9 OCT 2013, DOI: 10.1002/jssc.201300819

  15. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 29, Issue S1, May 2014, Pages: S1–S571,

    Version of Record online : 6 JUN 2014, DOI: 10.1002/mds.25914

  16. You have full text access to this OnlineOpen article
    A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

    European Journal of Neurology

    Volume 22, Issue 8, August 2015, Pages: 1184–1191, P. Barone, G. Santangelo, L. Morgante, M. Onofrj, G. Meco, G. Abbruzzese, U. Bonuccelli, G. Cossu, G. Pezzoli, P. Stanzione, L. Lopiano, A. Antonini and M. Tinazzi

    Version of Record online : 12 MAY 2015, DOI: 10.1111/ene.12724

  17. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition

    Journal of Neuroscience Research

    Volume 79, Issue 1-2, 1 - 15 January 2005, Pages: 172–179, Moussa B.H. Youdim, Orit Bar Am, Merav Yogev-Falach, Orly Weinreb, Wakako Maruyama, Makato Naoi and Tamar Amit

    Version of Record online : 30 NOV 2004, DOI: 10.1002/jnr.20350

  18. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  19. You have free access to this content
    Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline

    British Journal of Pharmacology

    Volume 143, Issue 3, October 2004, Pages: 371–378, Zaid A Abassi, Ofer Binah and Moussa B H Youdim

    Version of Record online : 17 FEB 2009, DOI: 10.1038/sj.bjp.0705962

  20. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

    Movement Disorders

    Volume 19, Issue 8, August 2004, Pages: 916–923, Matthew B. Stern, Kenneth L. Marek, Joseph Friedman, Robert A. Hauser, Peter A. LeWitt, Daniel Tarsy and C. Warren Olanow

    Version of Record online : 27 APR 2004, DOI: 10.1002/mds.20145